Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived Xenografts.

Lam HM, Nguyen HM, Labrecque MP, Brown LG, Coleman IM, Gulati R, Lakely B, Sondheim D, Chatterjee P, Marck BT, Matsumoto AM, Mostaghel EA, Schweizer MT, Nelson PS, Corey E.

Eur Urol. 2019 Jun 18. pii: S0302-2838(19)30449-X. doi: 10.1016/j.eururo.2019.05.042. [Epub ahead of print]

PMID:
31227306
2.

Genomic distinctions between metastatic lower and upper tract urothelial carcinoma revealed through rapid autopsy.

Winters BR, De Sarkar N, Arora S, Bolouri H, Jana S, Vakar-Lopez F, Cheng HH, Schweizer MT, Yu EY, Grivas P, Lee JK, Kollath L, Holt SK, McFerrin L, Ha G, Nelson PS, Montgomery RB, Wright JL, Lam HM, Hsieh AC.

JCI Insight. 2019 May 30;5. pii: 128728. doi: 10.1172/jci.insight.128728.

3.

Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene Mutations.

Schweizer MT, Antonarakis ES, Bismar TA, Guedes LB, Cheng HH, Tretiakova MS, Vakar-Lopez F, Klemfuss N, Konnick EQ, Mostaghel EA, Hsieh AC, Nelson PS, Yu EY, Montgomery RB, True LD, Epstein JI, Lotan TL, Pritchard CC.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00327. Epub 2019 Apr 18.

4.

In Reply.

Brennen WN, Schweizer MT, Wang H, Bivalacqua TJ, Partin AW, Lim SJ, Chapman C, Abdallah R, Levy O, Bhowmick NA, Karp JM, De Marzo A, Isaacs JT, Denmeade SR.

Stem Cells Transl Med. 2019 Jul;8(7):739-740. doi: 10.1002/sctm.19-0068. Epub 2019 Mar 29. No abstract available.

5.

Clinical determinants for successful circulating tumor DNA analysis in prostate cancer.

Schweizer MT, Gulati R, Beightol M, Konnick EQ, Cheng HH, Klemfuss N, De Sarkar N, Yu EY, Montgomery RB, Nelson PS, Pritchard CC.

Prostate. 2019 May;79(7):701-708. doi: 10.1002/pros.23778. Epub 2019 Mar 13.

PMID:
30865311
6.

Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations.

Marshall CH, Sokolova AO, McNatty AL, Cheng HH, Eisenberger MA, Bryce AH, Schweizer MT, Antonarakis ES.

Eur Urol. 2019 Feb 21. pii: S0302-2838(19)30110-1. doi: 10.1016/j.eururo.2019.02.002. [Epub ahead of print]

PMID:
30797618
7.

A Phase I Study to Assess the Safety and Cancer-Homing Ability of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells in Men with Localized Prostate Cancer.

Schweizer MT, Wang H, Bivalacqua TJ, Partin AW, Lim SJ, Chapman C, Abdallah R, Levy O, Bhowmick NA, Karp JM, De Marzo A, Isaacs JT, Brennen WN, Denmeade SR.

Stem Cells Transl Med. 2019 May;8(5):441-449. doi: 10.1002/sctm.18-0230. Epub 2019 Feb 8.

8.

Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.

Rodrigues DN, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, Seed G, Mateo J, Riisnaes R, Mullane S, Margolis C, Miao D, Miranda S, Dolling D, Clarke M, Bertan C, Crespo M, Boysen G, Ferreira A, Sharp A, Figueiredo I, Keliher D, Aldubayan S, Burke KP, Sumanasuriya S, Fontes MS, Bianchini D, Zafeiriou Z, Mendes LST, Mouw K, Schweizer MT, Pritchard CC, Salipante S, Taplin ME, Beltran H, Rubin MA, Cieslik M, Robinson D, Heath E, Schultz N, Armenia J, Abida W, Scher H, Lord C, D'Andrea A, Sawyers CL, Chinnaiyan AM, Alimonti A, Nelson PS, Drake CG, Van Allen EM, de Bono JS.

J Clin Invest. 2018 Nov 1;128(11):5185. doi: 10.1172/JCI125184. Epub 2018 Nov 1. No abstract available.

9.

Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.

Nava Rodrigues D, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, Seed G, Mateo J, Riisnaes R, Mullane S, Margolis C, Miao D, Miranda S, Dolling D, Clarke M, Bertan C, Crespo M, Boysen G, Ferreira A, Sharp A, Figueiredo I, Keliher D, Aldubayan S, Burke KP, Sumanasuriya S, Fontes MS, Bianchini D, Zafeiriou Z, Teixeira Mendes LS, Mouw K, Schweizer MT, Pritchard CC, Salipante S, Taplin ME, Beltran H, Rubin MA, Cieslik M, Robinson D, Heath E, Schultz N, Armenia J, Abida W, Scher H, Lord C, D'Andrea A, Sawyers CL, Chinnaiyan AM, Alimonti A, Nelson PS, Drake CG, Van Allen EM, de Bono JS.

J Clin Invest. 2018 Oct 1;128(10):4441-4453. doi: 10.1172/JCI121924. Epub 2018 Sep 4. Erratum in: J Clin Invest. 2018 Nov 1;128(11):5185.

10.

Correction: A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer.

Schweizer MT, Haugk K, McKiernan JS, Gulati R, Cheng HH, Maes JL, Dumpit RF, Nelson PS, Montgomery B, McCune JS, Plymate SR, Yu EY.

PLoS One. 2018 Aug 15;13(8):e0202709. doi: 10.1371/journal.pone.0202709. eCollection 2018.

11.

A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer.

Schweizer MT, Haugk K, McKiernan JS, Gulati R, Cheng HH, Maes JL, Dumpit RF, Nelson PS, Montgomery B, McCune JS, Plymate SR, Yu EY.

PLoS One. 2018 Jun 1;13(6):e0198389. doi: 10.1371/journal.pone.0198389. eCollection 2018. Erratum in: PLoS One. 2018 Aug 15;13(8):e0202709.

12.

Microsatellite instability in prostate cancer by PCR or next-generation sequencing.

Hempelmann JA, Lockwood CM, Konnick EQ, Schweizer MT, Antonarakis ES, Lotan TL, Montgomery B, Nelson PS, Klemfuss N, Salipante SJ, Pritchard CC.

J Immunother Cancer. 2018 Apr 17;6(1):29. doi: 10.1186/s40425-018-0341-y.

13.

Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.

Teply BA, Wang H, Luber B, Sullivan R, Rifkind I, Bruns A, Spitz A, DeCarli M, Sinibaldi V, Pratz CF, Lu C, Silberstein JL, Luo J, Schweizer MT, Drake CG, Carducci MA, Paller CJ, Antonarakis ES, Eisenberger MA, Denmeade SR.

Lancet Oncol. 2018 Jan;19(1):76-86. doi: 10.1016/S1470-2045(17)30906-3. Epub 2017 Dec 14.

14.

Supraphysiologic Testosterone Therapy in the Treatment of Prostate Cancer: Models, Mechanisms and Questions.

Mohammad OS, Nyquist MD, Schweizer MT, Balk SP, Corey E, Plymate S, Nelson PS, Mostaghel EA.

Cancers (Basel). 2017 Dec 6;9(12). pii: E166. doi: 10.3390/cancers9120166. Review.

15.

Hormone levels following surgical and medical castration: defining optimal androgen suppression.

Schweizer MT, Hancock ML, Getzenberg RH, Yu EY.

Asian J Androl. 2018 Jul-Aug;20(4):405-406. doi: 10.4103/aja.aja_38_17. No abstract available.

16.

Metastatic Adenocarcinoma of the Epididymis: A Case Report and Brief Literature Review.

Graham L, True LD, Schweizer MT.

Clin Genitourin Cancer. 2018 Apr;16(2):e335-e338. doi: 10.1016/j.clgc.2017.09.012. Epub 2017 Oct 3. Review. No abstract available.

PMID:
29066074
17.

Prognostic and therapeutic implications of DNA repair gene mutations in advanced prostate cancer.

Schweizer MT, Antonarakis ES.

Clin Adv Hematol Oncol. 2017 Oct;15(10):785-795. Review.

PMID:
29040258
18.

MSH2 Loss in Primary Prostate Cancer.

Guedes LB, Antonarakis ES, Schweizer MT, Mirkheshti N, Almutairi F, Park JC, Glavaris S, Hicks J, Eisenberger MA, De Marzo AM, Epstein JI, Isaacs WB, Eshleman JR, Pritchard CC, Lotan TL.

Clin Cancer Res. 2017 Nov 15;23(22):6863-6874. doi: 10.1158/1078-0432.CCR-17-0955. Epub 2017 Aug 8.

19.

Durable Response to Immune Checkpoint Blockade in a Platinum-Refractory Patient With Nonseminomatous Germ Cell Tumor.

Chi EA, Schweizer MT.

Clin Genitourin Cancer. 2017 Oct;15(5):e855-e857. doi: 10.1016/j.clgc.2017.04.005. Epub 2017 Apr 12. No abstract available.

PMID:
28465048
20.

Bipolar Androgen Therapy: A Paradoxical Approach for the Treatment of Castration-resistant Prostate Cancer.

Schweizer MT, Antonarakis ES, Denmeade SR.

Eur Urol. 2017 Sep;72(3):323-325. doi: 10.1016/j.eururo.2017.03.022. Epub 2017 Mar 29.

21.

AR-Signaling in Human Malignancies: Prostate Cancer and Beyond.

Schweizer MT, Yu EY.

Cancers (Basel). 2017 Jan 11;9(1). pii: E7. doi: 10.3390/cancers9010007. Review.

22.

Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate.

Schweizer MT, Cheng HH, Tretiakova MS, Vakar-Lopez F, Klemfuss N, Konnick EQ, Mostaghel EA, Nelson PS, Yu EY, Montgomery B, True LD, Pritchard CC.

Oncotarget. 2016 Dec 13;7(50):82504-82510. doi: 10.18632/oncotarget.12697.

23.

Targeting intratumoral androgens: statins and beyond.

Schweizer MT, Yu EY.

Ther Adv Med Oncol. 2016 Sep;8(5):388-95. doi: 10.1177/1758834016647962. Epub 2016 May 11. Review.

24.

Response: letter to the editor.

Schweizer MT, Plymate SR.

Expert Opin Ther Targets. 2017 Feb;21(2):229. doi: 10.1080/14728222.2016.1214400. Epub 2016 Aug 17. No abstract available.

PMID:
27494249
25.

Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study.

Schweizer MT, Wang H, Luber B, Nadal R, Spitz A, Rosen DM, Cao H, Antonarakis ES, Eisenberger MA, Carducci MA, Paller C, Denmeade SR.

Prostate. 2016 Sep;76(13):1218-26. doi: 10.1002/pros.23209. Epub 2016 Jun 24.

PMID:
27338150
26.

A Pilot Study of Clinical Targeted Next Generation Sequencing for Prostate Cancer: Consequences for Treatment and Genetic Counseling.

Cheng HH, Klemfuss N, Montgomery B, Higano CS, Schweizer MT, Mostaghel EA, McFerrin LG, Yu EY, Nelson PS, Pritchard CC.

Prostate. 2016 Oct;76(14):1303-11. doi: 10.1002/pros.23219. Epub 2016 Jun 21.

27.

Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer.

Schweizer MT, Gulati R, Mostaghel EA, Nelson PS, Montgomery RB, Yu EY, Cheng HH.

Med Oncol. 2016 Jul;33(7):77. doi: 10.1007/s12032-016-0793-1. Epub 2016 Jun 14.

28.

Targeting persistent androgen receptor signaling in castration-resistant prostate cancer.

Graham L, Schweizer MT.

Med Oncol. 2016 May;33(5):44. doi: 10.1007/s12032-016-0759-3. Epub 2016 Apr 4. Review.

PMID:
27042852
29.

Targeting constitutively active androgen receptor splice variants in castration resistant prostate cancer.

Schweizer MT, Plymate SR.

Expert Opin Ther Targets. 2016 Aug;20(8):903-6. doi: 10.1517/14728222.2016.1159676. Epub 2016 Mar 21. No abstract available.

30.

Persistent androgen receptor addiction in castration-resistant prostate cancer.

Schweizer MT, Yu EY.

J Hematol Oncol. 2015 Nov 13;8:128. doi: 10.1186/s13045-015-0225-2. Review.

31.

Liquid biopsy: Clues on prostate cancer drug resistance.

Schweizer MT, Antonarakis ES.

Sci Transl Med. 2015 Nov 4;7(312):312fs45. doi: 10.1126/scitranslmed.aad4008.

PMID:
26537254
32.

Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.

Maughan BL, Xhou XC, Suzman DL, Nadal R, Bassi S, Schweizer MT, Antonarakis ES.

Prostate. 2015 Nov;75(15):1814-20. doi: 10.1002/pros.23064. Epub 2015 Aug 26.

PMID:
26306637
33.

Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study.

Schweizer MT, Antonarakis ES, Wang H, Ajiboye AS, Spitz A, Cao H, Luo J, Haffner MC, Yegnasubramanian S, Carducci MA, Eisenberger MA, Isaacs JT, Denmeade SR.

Sci Transl Med. 2015 Jan 7;7(269):269ra2. doi: 10.1126/scitranslmed.3010563.

34.

Clinical activity of enzalutamide in Docetaxel-naïve and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancer.

Nadal R, Zhang Z, Rahman H, Schweizer MT, Denmeade SR, Paller CJ, Carducci MA, Eisenberger MA, Antonarakis ES.

Prostate. 2014 Nov;74(15):1560-8. doi: 10.1002/pros.22874. Epub 2014 Aug 31.

35.

Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone.

Suzman DL, Luber B, Schweizer MT, Nadal R, Antonarakis ES.

Prostate. 2014 Sep;74(13):1278-85. doi: 10.1002/pros.22844. Epub 2014 Jul 22.

36.

The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer.

Schweizer MT, Zhou XC, Wang H, Bassi S, Carducci MA, Eisenberger MA, Antonarakis ES.

Eur Urol. 2014 Oct;66(4):646-52. doi: 10.1016/j.eururo.2014.01.018. Epub 2014 Jan 24.

37.

Immunotherapy for prostate cancer: recent developments and future challenges.

Schweizer MT, Drake CG.

Cancer Metastasis Rev. 2014 Sep;33(2-3):641-55. doi: 10.1007/s10555-013-9479-8. Review.

38.

Chemotherapy and its evolving role in the management of advanced prostate cancer.

Schweizer MT, Antonarakis ES.

Asian J Androl. 2014 May-Jun;16(3):334-40. doi: 10.4103/1008-682X.122593. Review.

39.

Pharmacodynamic study of disulfiram in men with non-metastatic recurrent prostate cancer.

Schweizer MT, Lin J, Blackford A, Bardia A, King S, Armstrong AJ, Rudek MA, Yegnasubramanian S, Carducci MA.

Prostate Cancer Prostatic Dis. 2013 Dec;16(4):357-61. doi: 10.1038/pcan.2013.28. Epub 2013 Aug 20.

40.

Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy.

Schweizer MT, Zhou XC, Wang H, Yang T, Shaukat F, Partin AW, Eisenberger MA, Antonarakis ES.

Ann Oncol. 2013 Nov;24(11):2881-6. doi: 10.1093/annonc/mdt335. Epub 2013 Aug 14.

41.

Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trials.

Schweizer MT, Huang P, Kattan MW, Kibel AS, de Wit R, Sternberg CN, Epstein JI, Eisenberger MA.

Cancer. 2013 Oct 15;119(20):3610-8. doi: 10.1002/cncr.28270. Epub 2013 Aug 13.

42.

From bevacizumab to tasquinimod: angiogenesis as a therapeutic target in prostate cancer.

Schweizer MT, Carducci MA.

Cancer J. 2013 Jan-Feb;19(1):99-106. doi: 10.1097/PPO.0b013e31827e0b86. Review.

PMID:
23337763
43.

Abiraterone acetate: a hat trick of clinical benefits.

Schweizer MT, Antonarakis ES.

Lancet Oncol. 2012 Dec;13(12):1173-4. doi: 10.1016/S1470-2045(12)70460-6. Epub 2012 Nov 9. No abstract available.

44.

Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born.

Schweizer MT, Antonarakis ES.

Ther Adv Urol. 2012 Aug;4(4):167-78. doi: 10.1177/1756287212452196.

45.

Takotsubo cardiomyopathy in a patient with squamous cell esophageal carcinoma.

Schweizer MT, Mehta R, Salgia R, Villaflor VM.

J Clin Oncol. 2011 Jul 10;29(20):e598-600. doi: 10.1200/JCO.2011.35.1791. Epub 2011 Apr 25. No abstract available.

PMID:
21519014

Supplemental Content

Loading ...
Support Center